MX340264B - Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. - Google Patents

Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.

Info

Publication number
MX340264B
MX340264B MX2012006879A MX2012006879A MX340264B MX 340264 B MX340264 B MX 340264B MX 2012006879 A MX2012006879 A MX 2012006879A MX 2012006879 A MX2012006879 A MX 2012006879A MX 340264 B MX340264 B MX 340264B
Authority
MX
Mexico
Prior art keywords
copd
aerosol formulation
patients
administration
invention concerns
Prior art date
Application number
MX2012006879A
Other languages
English (en)
Other versions
MX2012006879A (es
Inventor
Bonelli Sauro
Usberti Francesca
Zambelli Enrico
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340264(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2012006879A publication Critical patent/MX2012006879A/es
Publication of MX340264B publication Critical patent/MX340264B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/10—Adding propellants in solid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formulaciones de una solución en aerosol estable que comprende bromuro de glicopirronio para la administración a los pacientes con COPO y otras condiciones respiratorias.
MX2012006879A 2009-12-23 2010-12-22 Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica. MX340264B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015980 2009-12-23
PCT/EP2010/070478 WO2011076842A2 (en) 2009-12-23 2010-12-22 Aerosol formulation for copd

Publications (2)

Publication Number Publication Date
MX2012006879A MX2012006879A (es) 2012-07-04
MX340264B true MX340264B (es) 2016-07-04

Family

ID=42046446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006879A MX340264B (es) 2009-12-23 2010-12-22 Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.

Country Status (31)

Country Link
US (5) US20110150783A1 (es)
EP (1) EP2515854B1 (es)
JP (1) JP5800829B2 (es)
KR (1) KR101747474B1 (es)
CN (1) CN102665680B (es)
AU (2) AU2010334858A1 (es)
CA (1) CA2785317C (es)
CL (1) CL2012001668A1 (es)
CO (1) CO6551734A2 (es)
CY (1) CY1115109T1 (es)
DK (1) DK2515854T3 (es)
EA (1) EA021604B1 (es)
ES (1) ES2464520T3 (es)
GE (1) GEP20166479B (es)
HR (1) HRP20140550T1 (es)
IL (1) IL220534A0 (es)
MA (1) MA33821B1 (es)
MX (1) MX340264B (es)
MY (1) MY156950A (es)
NZ (1) NZ600789A (es)
PE (1) PE20121467A1 (es)
PH (1) PH12012501063A1 (es)
PL (1) PL2515854T3 (es)
PT (1) PT2515854E (es)
RS (1) RS53355B (es)
SG (1) SG181870A1 (es)
SI (1) SI2515854T1 (es)
TN (1) TN2012000261A1 (es)
UA (1) UA106098C2 (es)
WO (1) WO2011076842A2 (es)
ZA (1) ZA201204613B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914354B2 (ja) 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
GEP20166479B (en) * 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
CN102665678B (zh) * 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
HRP20181551T1 (hr) * 2013-12-30 2018-11-30 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
EP3607936B1 (en) * 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
EP4188327B1 (en) 2020-07-31 2025-05-28 Chemo Research, S.L. Combination therapy for inhalation administration
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
MX2023003754A (es) 2020-10-09 2023-04-24 Chiesi Farm Spa Formulacion farmaceutica para inhalador presurizado de dosis medidas.
EP4531921A1 (en) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
RO121172B1 (ro) * 2001-03-30 2007-01-30 Jago Research Ag Compoziţie farmaceutică de aerosol şi utilizarea acesteia
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
PT3494995T (pt) 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
CN1726038A (zh) 2002-12-16 2006-01-25 贝林格尔英格海姆法玛两合公司 含有噻托铵的hfc溶液剂
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH &amp; CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2200550B1 (en) 2007-10-18 2018-04-18 Rose U, LLC Topical glycopyrrolate formulations
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102695496B (zh) * 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
GEP20166479B (en) * 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
CN102665678B (zh) * 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
EP3143987A1 (en) * 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
MY176191A (en) 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
HRP20181551T1 (hr) * 2013-12-30 2018-11-30 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola

Also Published As

Publication number Publication date
JP2013515695A (ja) 2013-05-09
US12357568B2 (en) 2025-07-15
US11590074B2 (en) 2023-02-28
NZ600789A (en) 2014-09-26
AU2016234894B2 (en) 2018-02-22
CA2785317C (en) 2018-02-27
EP2515854B1 (en) 2014-03-19
ZA201204613B (en) 2013-09-25
AU2016234894A1 (en) 2016-10-13
PE20121467A1 (es) 2012-11-07
MA33821B1 (fr) 2012-12-03
CN102665680A (zh) 2012-09-12
CO6551734A2 (es) 2012-10-31
EP2515854A2 (en) 2012-10-31
ES2464520T3 (es) 2014-06-03
WO2011076842A3 (en) 2011-12-01
EA021604B1 (ru) 2015-07-30
TN2012000261A1 (en) 2013-12-12
WO2011076842A2 (en) 2011-06-30
US20210000738A1 (en) 2021-01-07
PH12012501063A1 (en) 2013-02-04
MX2012006879A (es) 2012-07-04
RS53355B (sr) 2014-10-31
GEP20166479B (en) 2016-05-25
US20250262151A1 (en) 2025-08-21
EA201290374A1 (ru) 2013-01-30
BR112012015336A2 (pt) 2016-03-15
MY156950A (en) 2016-04-15
CY1115109T1 (el) 2016-12-14
SI2515854T1 (sl) 2014-07-31
US10806701B2 (en) 2020-10-20
PT2515854E (pt) 2014-05-27
CN102665680B (zh) 2014-07-30
HK1174568A1 (en) 2013-06-14
HRP20140550T1 (hr) 2014-07-18
US20110150783A1 (en) 2011-06-23
SG181870A1 (en) 2012-07-30
PL2515854T3 (pl) 2014-08-29
DK2515854T3 (da) 2014-05-26
AU2010334858A1 (en) 2012-07-12
UA106098C2 (uk) 2014-07-25
JP5800829B2 (ja) 2015-10-28
CL2012001668A1 (es) 2012-12-07
US20230157951A1 (en) 2023-05-25
IL220534A0 (en) 2012-08-30
KR101747474B1 (ko) 2017-06-14
KR20120120160A (ko) 2012-11-01
CA2785317A1 (en) 2011-06-30
US20150306026A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
TN2012000261A1 (en) Aerosol formulation for copd
IL216468A0 (en) Compositions, methods &amp; systems for respiratory respiratory delivery of two or more active agents
MX348823B (es) Formulaciones estables de linaclotida.
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011076840A3 (en) Aerosol formulation for copd
EP2846839A4 (en) FORMULATIONS FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES
MX345263B (es) Formulación de pexiganan estable.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
IN2014DN10134A (es)
MX2015004310A (es) Formulacion de aroma y fragancia (v).
UA92872C2 (ru) Комбинированное антиагрегантное и антиоксидантное лекарственное средство
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
UA59396U (ru) Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals
UA92273C2 (ru) Использование углекислотного экстракта хмеля в качестве активной субстанции в фармацевтических композициях с противомикробным действием

Legal Events

Date Code Title Description
FG Grant or registration